Date: 2015-04-10
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Genzyme (USA - MA), a Sanofi company (France)
Product: GZ389988
Action
mechanism: GZ389988 (TrKA) is a small molecule which inhibits binding of nerve growth factor (NGF) to its primary TrkA receptor, and is being developed as a treatment for pain resulting from osteoarthritis.
Disease: osteoarthritis
Therapeutic area: Inflammatory diseases - Rheumatic diseases
Country: Germany
Trial
details: This two part protocol will assess the safety, tolerability, and pharmacokinetics of single escalating intra-articular doses followed by assessment of efficacy, safety, tolerability and pharmacokinetics of a single intra-articular dose of the TrkA Inhibitor, GZ389988, in patients with painful psteoarthritis of the knee. (NCT02424942)
Latest
news: The molecule is currently in Phase I with enrollment completed in October 2015.
